Recent advances with 5‐HT3 modulators for neuropsychiatric and gastrointestinal disorders. Issue 5 (1st March 2020)

• Record Type: Journal Article
• Authors: Juza, Radomir; Vlcek, Premysl; Mezeiova, Eva; Musilek, Kamil; Soukup, Ondrej; Korabecny, Jan
• Is Part Of: Medicinal research reviews. Volume 40:Issue 5(2020)
• Page Start: 1593
• Page End: 1678
• Publication Date: 2020-03-01
• Subjects: 5‐HT3 receptor modulators -- psychosis -- schizophrenia -- serotonin -- structure‐activity relationship; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; 615
• DOI: 10.1002/med.21666
• Languages: English
• ISSNs: 0198-6325

Abstract

Abstract: Serotonin (5‐hydroxytryptophan [5‐HT]) is a biologically active amine expressed in platelets, in gastrointestinal (GI) cells and, to a lesser extent, in the central nervous system (CNS). This biogenic compound acts through the activation of seven 5‐HT receptors (5‐HT1‐7 Rs). The 5‐HT3 R is a ligand‐gated ion channel belonging to the Cys‐loop receptor family. There is a wide variety of 5‐HT3 R modulators, but only receptor antagonists (known as setrons) have been used clinically for chemotherapy‐induced nausea and vomiting and irritable bowel syndrome treatment. However, since the discovery of the setrons in the mid‐1980s, a large number of studies have been published exploring new potential applications due their potency in the CNS and mild side effects. The results of these studies have revealed new potential applications, including the treatment of neuropsychiatric disorders such as schizophrenia, depression, anxiety, and drug abuse. In this review, we provide information related to therapeutic potential of 5‐HT3 R antagonists on GI and neuropsychiatric disorders. The major attention is paid to the structure, function, and pharmacology of novel 5‐HT3 R modulators developed over the past 10 years.